UNLIMITED TURBO BULL - VERTEX PHARMACEUTICALS | Real-time Euronext Paris 14:48:42 29/04/2024 BST | ||
| 2.739 EUR | -0.62% |
|
| Current month | -12.37% | ||
| 1 month | -11.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 2.739 | -0.62% | 18 |
| 26/04/24 | 2.756 | +0.33% | 62 |
| 25/04/24 | 2.747 | -1.47% | 67 |
| 24/04/24 | 2.788 | -3.09% | 65 |
| 23/04/24 | 2.877 | +1.95% | 43 |
Real-time Euronext Paris
Last update April 29, 2024 at 02:48 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| AG80S | |
| ISIN | DE000SH8KHY7 |
| Date issued | 08/04/2022 |
| Strike | 252 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 1.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.972 € |
|---|---|
| Lowest since issue | 0.359 € |
| Spread | 0.121 € |
| Spread % | 4.39% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
397.5
USD
Average target price
459.7
USD
Spread / Average Target
+15.66%
- Stock Market
- Certificates
- AG80S Certificat
